PTC Therapeutics Inc (PTCT) - Total Assets
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) holds total assets worth $2.87 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore PTC Therapeutics Inc (PTCT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
PTC Therapeutics Inc - Total Assets Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See PTC Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
PTC Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
PTC Therapeutics Inc's total assets of $2.87 Billion consist of 78.1% current assets and 21.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.8% |
| Accounts Receivable | $181.62 Million | 6.2% |
| Inventory | $79.65 Million | 2.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $388.75 Million | 13.4% |
| Goodwill | $82.34 Million | 2.8% |
Asset Composition Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PTCT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PTC Therapeutics Inc's current assets represent 78.1% of total assets in 2025, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2025, up from 17.4% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 13.4% of total assets.
PTC Therapeutics Inc Competitors by Total Assets
Key competitors of PTC Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
PTC Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.44 | 3.89 | 3.66 |
| Quick Ratio | 2.36 | 3.85 | 3.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.33 Billion | $1.72 Billion | $775.27 Million |
PTC Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between PTC Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1743.27 |
| Latest Market Cap to Assets Ratio | 1.94 |
| Asset Growth Rate (YoY) | 70.7% |
| Total Assets | $2.91 Billion |
| Market Capitalization | $5.64 Billion USD |
Valuation Analysis
Above Book Valuation: The market values PTC Therapeutics Inc's assets above their book value (1.94x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: PTC Therapeutics Inc's assets grew by 70.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PTC Therapeutics Inc (2004–2025)
The table below shows the annual total assets of PTC Therapeutics Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.91 Billion | +70.75% |
| 2024-12-31 | $1.71 Billion | -10.06% |
| 2023-12-31 | $1.90 Billion | +11.14% |
| 2022-12-31 | $1.71 Billion | -11.99% |
| 2021-12-31 | $1.94 Billion | -12.24% |
| 2020-12-31 | $2.21 Billion | +36.00% |
| 2019-12-31 | $1.62 Billion | +45.08% |
| 2018-12-31 | $1.12 Billion | +185.77% |
| 2017-12-31 | $391.65 Million | +45.41% |
| 2016-12-31 | $269.35 Million | -26.82% |
| 2015-12-31 | $368.04 Million | +10.45% |
| 2014-12-31 | $333.22 Million | +119.36% |
| 2013-12-31 | $151.90 Million | +1062.02% |
| 2012-12-31 | $13.07 Million | -70.39% |
| 2011-12-31 | $44.15 Million | +0.40% |
| 2005-12-31 | $43.97 Million | +12.85% |
| 2004-12-31 | $38.97 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more